arrow
R

Rodryg Ramlau

Poznan University of Medical Sciences
H指数:53
被引数:2.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study

Xevinapant联合avelumab治疗晚期实体瘤,并在晚期非小细胞肺癌中进行剂量扩展:一项开放标签、非随机 Ib 期研究的探索性生物标志物、安全性和有效性分析

2025-05-080
OA
Leveraging innate and adaptive immunity with AFM24 and atezolizumab in metastatic gastric cancer

利用AFM24和atezolizumab增强固有免疫和适应性免疫在转移性胃癌中的应用

2024-09-010
PRE
Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations
2024-04-161
OAAI
Xevinapant plus avelumab in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Phase 1b dose-expansion results and exploratory biomarker analyses
2023-04-140
PRE
ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA
2022-05-015
OAAI
Tissue MicroRNA Expression as a Predictor of Response to Immunotherapy in NSCLC Patients
2021-02-0813
OAAI
Assessment of EGFR gene mutations in circulating free DNA in monitoring of response to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma
2020-01-012
OAAI